FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is a pharmaceutical composition for peroral introduction for treatment of malignant tumours in a patient, excluding non-Hodgkin's lymphoma, myelodysplastic syndrome, leukemia and malignant tumours with leukocyte infiltration, which contains up to 400 mg of the solid drug form of suberoylanilide hydroxamic acid (SAHA), or its pharmaceutically acceptable salt, or a hydrate.
EFFECT: solid drug form of SAHA, which has a crystalline structure was characterised by stability and provided partial reaction of a malignant tumour of the larynx with metastases or shrinkage of the solid tumour by results of CT-scanning.
22 cl, 12 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF INDUCING TERMINAL DIFFERENTIATION | 2003 |
|
RU2394022C2 |
| METHOD OF INDUCTION OF TERMINAL DIFFERENTIATION | 2003 |
|
RU2320331C2 |
| COMBINATIONS OF SPECIFIC CLASS I HISTONE DEACETYLASE INHIBITORS AND PROTEASOME INHIBITORS | 2007 |
|
RU2456990C2 |
| COMBINATION OF A HISTONE DEACETYLASE INHIBITOR AND A PROTEIN KINASE INHIBITOR AND PHARMACEUTICAL APPLICATION THEREOF | 2019 |
|
RU2770754C1 |
| METHODS OF REDUCING CACHEXIA ASSOCIATED WITH CANCER | 2014 |
|
RU2692785C1 |
| METHODS AND COMPOSITIONS FOR TREATING TUMORS | 2017 |
|
RU2741786C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI-PD-L1 ANTIBODY | 2020 |
|
RU2824577C1 |
| DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
| HYSTONE DESACETYLASE INHIBITORS FROM NOVEL BENZAMIDE DERIVATIVES WITH STRONG DIFFERENTIAL ANTI-PROLOFERATIVE ACTIVITY | 2004 |
|
RU2364589C2 |
| METHODS FOR CANCER TREATMENT USING AUTOPHAGY INHIBITOR BASED ON THIOXANTHONE | 2011 |
|
RU2627588C2 |
